DOP02: The dose-dependent effect of enteral nutrition on faecal microbial metabolites of healthy volunteersECCO'20 Vienna 2020
1
DOP03: The impact of elemental diet on the human gut microbial structure and intestinal metabolitesECCO'20 Vienna 2020
1
DOP04: Matching between donors and patients in fecal microbiota transplantation is important for long-term maintenance on Ulcerative ColitisECCO'20 Vienna 2020
1
DOP06: Non-invasive identification of adherent-invasive E. coli in patients with Crohn's DiseaseECCO'20 Vienna 2020
1
DOP07: Long-term results of 4.5 Years of fecal microbiota transplantation for treatment of Refractory Ulcerative ColitisECCO'20 Vienna 2020
1
DOP08: Deep remission in paediatric Crohn’s Disease is associated with increased abundance of Dialister species and increased valerateECCO'20 Vienna 2020
1
DOP10: Intestinal ultrasound response and transmural healing after ustekinumab induction in Crohn’s Disease: Week 16 interim analysis of the STARDUST trial substudyECCO'20 Vienna 2020
1
DOP11: Normalisation of faecal calprotectin within 12 months of diagnosis is associated with a reduced risk of disease progression in Crohn's DiseaseECCO'20 Vienna 2020
1
DOP13: Clinical and endoscopic response to ustekinumab in Crohn’s Disease: Week 16 interim analysis of the STARDUST trialECCO'20 Vienna 2020
1
DOP15: Transmural healing with vedolizumab in patients with active Crohn’s DiseaseECCO'20 Vienna 2020
1
DOP16: An evaluation of the exposure-efficacy relationship for subcutaneous vedolizumab maintenance treatment of Crohn’s Disease: Pharmacokinetic findings from VISIBLE 2ECCO'20 Vienna 2020
1
DOP17: Identification of biomarkers and mechanistic insight for upadacitinib in Ulcerative Colitis: Analysis of serum inflammatory mediators in the phase 2b U-ACHIEVE studyECCO'20 Vienna 2020
1
DOP18: Impact of adherence to anti- tumor necrosis factor therapy on clinical outcomes in Crohn's Disease: A nationwide population-based studyECCO'20 Vienna 2020
1
DOP19: Real-world healthcare resource utilisation among patients with Inflammatory Bowel Disease administered vedolizumab for 6 monthsECCO'20 Vienna 2020
1
DOP20: Can lifestyle and psychosocial factors predict flares of IBD; an exploratory study using telemedicineECCO'20 Vienna 2020
1
DOP21: Time to first treatment with biologic agents for Ulcerative Colitis and Crohn’s Disease across four Nordic countries: Results from the TRINordic studyECCO'20 Vienna 2020
1